Pomalidomide
Pomalyst · Immunomodulatory drug (IMiD)
Tumor lysis; usable in renal impairment.
Thalomid · THAL
Immunomodulatory drug (IMiD) · approved 2006 · 6 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
The original IMiD, whose kidney risk is dominated by tumor lysis and reduced perfusion rather than direct nephrotoxicity.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Thalidomide is not a direct nephrotoxin; the principal renal hazard is tumor lysis syndrome, which is uncommon in myeloma and reported at the case level. Sinus bradycardia is a recognized dose-related non-renal effect that, with the drug’s sedative/hypotensive properties, can compound prerenal physiology. Venous thromboembolism is the other dominant class toxicity.Source: Chang et al., Chang Gung Med J 2011
Tumor lysis within days of initiation in high-burden disease.
Distilled from: “Tumor lysis within days of initiation in high-burden disease; bradycardia over weeks of dosing.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Tap a signature to trace where it strikes the nephron.
Functional / pre-renal — reduced perfusion upstream of the nephron; no single structural segment is injured.
Prerenal / Hemodynamic AKI: functional / pre-renal, no single structural segment injured.
Prerenal / Hemodynamic AKI
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Parent immunomodulatory drug that binds cereblon, inhibits angiogenesis (VEGF/bFGF), modulates cytokines (suppresses TNF-alpha), and co-stimulates T/NK cells. Used in multiple myeloma and erythema nodosum leprosum.
Class-level context for the major non-renal toxicities of the Immunomodulatory drug (IMiD) class.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
Hematologic
Cytopenias, thrombosis, TMA
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM See full prescribing information for complete boxed warning. EMBRYO-FETAL TOXICITY • If THALOMID is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. THALOMID should never be used by females who are pregnant or who could be pregnant while taking the drug. Even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects. • Pregnancy must be excluded before start of treatment. Prevent pregnancy thereafter by the use of two reliable methods of contraception. ( 5.1 , 8.3 ) THALOMID is only available through a restricted distribution program, the Thalidomide REMS program ( 5.2 ). VENOUS THROMBOEMBOLISM • Significant increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma receiving THALOMID with dexamethasone ( 5.3 ). EMBRYO-FETAL TOXICITY If THALOMID is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. THALOMID should never be used by females who are pregnant or who could become pregnant while taking the drug. Even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects. Because of this toxicity and in an effort to…
Kidney rows of the label's dosage tables
None of the newest openFDA labels for this product carries a dosage table. The label's prose can still give kidney instructions.
Everything below is FAERS — adverse events someone chose to report, about 19,824 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
3,485 of 19,824 reports
Reported with hospitalization
5,390 of 19,824 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 1,515 of the 19,824 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Thalidomide sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Pomalyst · Immunomodulatory drug (IMiD)
Tumor lysis; usable in renal impairment.
Etopophos · Topoisomerase II inhibitor
Tumor lysis; renally cleared.
Hydrea · Ribonucleotide reductase inhibitor
Tumor lysis in myeloproliferative disease.
Arranon · Purine analog
Tumor lysis in T-ALL.
Leustatin · Purine analog
Tumor lysis; high-dose nephrotoxicity.
Zevalin · Radioimmunotherapy (Y-90 anti-CD20)
Yttrium-90 radioimmunotherapy; tumor lysis with bulky lymphoma.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Thalidomide’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Thalidomide; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 141 clinical records among all 200 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.